Reviews Conjugated Estrogens


No reviews yet.

Premarin Drug Description
Premarin®
(conjugated estrogens) Tablets, USP

WARNINGS
ENDOMETRIAL CANCER
Adequate diagnostic measures, including endometrial sampling when indicated,
should be undertaken to rule out malignancy in all cases of undiagnosed persistent
or recurring abnormal vaginal bleeding. (See WARNINGS,
Malignant neoplasms, Endometrial cancer.)
CARDIOVASCULAR AND OTHER RISKS
Estrogens with or without progestins should not be used for the prevention
of cardiovascular disease or dementia. (See Clinical
Studies and WARNINGS, Cardiovascular
disorders and Dementia.)
The estrogen alone substudy of the Women's Health Initiative (WHI) reported
increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal
women (50 to 79 years of age) during 6.8 years and 7.1 years, respectively,
of treatment with daily oral conjugated estrogens (CE 0.625 mg), relative
to placebo. (See Clinical Studies and
WARNINGS, Cardiovascular disorders.)
The estrogen plus progestin substudy of WHI reported increased risks of myocardial
infarction, stroke, invasive breast cancer, pulmonary emboli, and DVT in postmenopausal
women (50 to 79 years of age) during 5.6 years of treatment with daily CE
0.625 mg combined with medroxyprogesterone acetate (MPA 2.5 mg), relative
to placebo. (See Clinical Studies and
WARNINGS, Cardiovascular disorders and
Malignant neoplasms, Breast cancer.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported
an increased risk of developing probable dementia in postmenopausal women
65 years of age or older during 5.2 years of treatment with daily CE 0.625
mg alone and during 4 years of treatment with daily CE 0.625 mg combined with
MPA 2.5 mg, relative to placebo. It is unknown whether this finding applies
to younger postmenopausal women. (See Clinical
Studies and WARNINGS, Dementia and
PRECAUTIONS, Geriatric Use.)
In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and MPA and other combinations and dosage forms of estrogens and progestins. Because of these risks, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

DRUG DESCRIPTION



What are the possible side effects of conjugated estrogens (Cenestin, Enjuvia, Premarin)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop taking this medication and call your doctor at once if you have any of these serious side effects:

chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, general ill feeling;
sudden numbness or weakness, especially on one side of the body;
sudden...
Read All Potential Side Effects for Premarin »




Premarin® (conjugated estrogens tablets, USP) for oral administration contains
a mixture of conjugated estrogens obtained exclusively from natural sources,
occurring as the sodium salts of water-soluble estrogen sulfates blended to
represent the average composition of material derived from pregnant mares' urine.
It is a mixture of sodium estrone sulfate and sodium equilin sulfate. It contains
as concomitant components, as sodium sulfate conjugates, 17α-dihydroequilin,
17α- estradiol, and 17β-dihydroequilin. Tablets for oral administration
are available in 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg, and 1.25 mg strengths of
conjugated estrogens.
Premarin 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg, and 1.25 mg tablets also contain the following inactive ingredients: calcium phosphate tribasic, hydroxypropyl cellulose, microcrystalline cellulose, powdered cellulose, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, sucrose, and titanium dioxide.
- 0.3 mg tablets also contain: D&C Yellow No. 10 and FD&C Blue
No. 2.
- 0.45 mg tablets also contain: FD&C Blue No. 2.
- 0.625 mg tablets also contain: FD&C Blue No. 2 and FD&C Red No.
40.
- 0.9 mg tablets also contain: D&C Red No. 30 and D&C Red No. 7.
- 1.25 mg tablets also contain: black iron oxide, D&C Yellow No. 10
and FD&C Yellow No. 6.
Premarin tablets comply with USP Dissolution Test criteria as outlined below:
Premarin 1.25 mg tablets                                                   USP
Dissolution Test 4
Premarin 0.3 mg, 0.45 mg and 0.625 mg tablets             USP
Dissolution Test 5
Premarin 0.9 mg tablets                                                     USP
Dissolution Test 6
Last reviewed on RxList: 3/28/2008




Premarin Drug Description
Premarin®
(conjugated estrogens) Tablets, USP

WARNINGS
ENDOMETRIAL CANCER
Adequate diagnostic measures, including endometrial sampling when indicated,
should be undertaken to rule out malignancy in all cases of undiagnosed persistent
or recurring abnormal vaginal bleeding. (See WARNINGS,
Malignant neoplasms, Endometrial cancer.)
CARDIOVASCULAR AND OTHER RISKS
Estrogens with or without progestins should not be used for the prevention
of cardiovascular disease or dementia. (See Clinical
Studies and WARNINGS, Cardiovascular
disorders and Dementia.)
The estrogen alone substudy of the Women's Health Initiative (WHI) reported
increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal
women (50 to 79 years of age) during 6.8 years and 7.1 years, respectively,
of treatment with daily oral conjugated estrogens (CE 0.625 mg), relative
to placebo. (See Clinical Studies and
WARNINGS, Cardiovascular disorders.)
The estrogen plus progestin substudy of WHI reported increased risks of myocardial
infarction, stroke, invasive breast cancer, pulmonary emboli, and DVT in postmenopausal
women (50 to 79 years of age) during 5.6 years of treatment with daily CE
0.625 mg combined with medroxyprogesterone acetate (MPA 2.5 mg), relative
to placebo. (See Clinical Studies and
WARNINGS, Cardiovascular disorders and
Malignant neoplasms, Breast cancer.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported
an increased risk of developing probable dementia in postmenopausal women
65 years of age or older during 5.2 years of treatment with daily CE 0.625
mg alone and during 4 years of treatment with daily CE 0.625 mg combined with
MPA 2.5 mg, relative to placebo. It is unknown whether this finding applies
to younger postmenopausal women. (See Clinical
Studies and WARNINGS, Dementia and
PRECAUTIONS, Geriatric Use.)
In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and MPA and other combinations and dosage forms of estrogens and progestins. Because of these risks, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

DRUG DESCRIPTION



What are the possible side effects of conjugated estrogens (Cenestin, Enjuvia, Premarin)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop taking this medication and call your doctor at once if you have any of these serious side effects:

chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, general ill feeling;
sudden numbness or weakness, especially on one side of the body;
sudden...
Read All Potential Side Effects for Premarin »




Premarin® (conjugated estrogens tablets, USP) for oral administration contains
a mixture of conjugated estrogens obtained exclusively from natural sources,
occurring as the sodium salts of water-soluble estrogen sulfates blended to
represent the average composition of material derived from pregnant mares' urine.
It is a mixture of sodium estrone sulfate and sodium equilin sulfate. It contains
as concomitant components, as sodium sulfate conjugates, 17α-dihydroequilin,
17α- estradiol, and 17β-dihydroequilin. Tablets for oral administration
are available in 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg, and 1.25 mg strengths of
conjugated estrogens.
Premarin 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg, and 1.25 mg tablets also contain the following inactive ingredients: calcium phosphate tribasic, hydroxypropyl cellulose, microcrystalline cellulose, powdered cellulose, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, sucrose, and titanium dioxide.
- 0.3 mg tablets also contain: D&C Yellow No. 10 and FD&C Blue
No. 2.
- 0.45 mg tablets also contain: FD&C Blue No. 2.
- 0.625 mg tablets also contain: FD&C Blue No. 2 and FD&C Red No.
40.
- 0.9 mg tablets also contain: D&C Red No. 30 and D&C Red No. 7.
- 1.25 mg tablets also contain: black iron oxide, D&C Yellow No. 10
and FD&C Yellow No. 6.
Premarin tablets comply with USP Dissolution Test criteria as outlined below:
Premarin 1.25 mg tablets                                                   USP
Dissolution Test 4
Premarin 0.3 mg, 0.45 mg and 0.625 mg tablets             USP
Dissolution Test 5
Premarin 0.9 mg tablets                                                     USP
Dissolution Test 6
Last reviewed on RxList: 3/28/2008




Premarin Drug Description
Premarin®
(conjugated estrogens) Tablets, USP

WARNINGS
ENDOMETRIAL CANCER
Adequate diagnostic measures, including endometrial sampling when indicated,
should be undertaken to rule out malignancy in all cases of undiagnosed persistent
or recurring abnormal vaginal bleeding. (See WARNINGS,
Malignant neoplasms, Endometrial cancer.)
CARDIOVASCULAR AND OTHER RISKS
Estrogens with or without progestins should not be used for the prevention
of cardiovascular disease or dementia. (See Clinical
Studies and WARNINGS, Cardiovascular
disorders and Dementia.)
The estrogen alone substudy of the Women's Health Initiative (WHI) reported
increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal
women (50 to 79 years of age) during 6.8 years and 7.1 years, respectively,
of treatment with daily oral conjugated estrogens (CE 0.625 mg), relative
to placebo. (See Clinical Studies and
WARNINGS, Cardiovascular disorders.)
The estrogen plus progestin substudy of WHI reported increased risks of myocardial
infarction, stroke, invasive breast cancer, pulmonary emboli, and DVT in postmenopausal
women (50 to 79 years of age) during 5.6 years of treatment with daily CE
0.625 mg combined with medroxyprogesterone acetate (MPA 2.5 mg), relative
to placebo. (See Clinical Studies and
WARNINGS, Cardiovascular disorders and
Malignant neoplasms, Breast cancer.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported
an increased risk of developing probable dementia in postmenopausal women
65 years of age or older during 5.2 years of treatment with daily CE 0.625
mg alone and during 4 years of treatment with daily CE 0.625 mg combined with
MPA 2.5 mg, relative to placebo. It is unknown whether this finding applies
to younger postmenopausal women. (See Clinical
Studies and WARNINGS, Dementia and
PRECAUTIONS, Geriatric Use.)
In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and MPA and other combinations and dosage forms of estrogens and progestins. Because of these risks, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

DRUG DESCRIPTION



What are the possible side effects of conjugated estrogens (Cenestin, Enjuvia, Premarin)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop taking this medication and call your doctor at once if you have any of these serious side effects:

chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, general ill feeling;
sudden numbness or weakness, especially on one side of the body;
sudden...
Read All Potential Side Effects for Premarin »




Premarin® (conjugated estrogens tablets, USP) for oral administration contains
a mixture of conjugated estrogens obtained exclusively from natural sources,
occurring as the sodium salts of water-soluble estrogen sulfates blended to
represent the average composition of material derived from pregnant mares' urine.
It is a mixture of sodium estrone sulfate and sodium equilin sulfate. It contains
as concomitant components, as sodium sulfate conjugates, 17α-dihydroequilin,
17α- estradiol, and 17β-dihydroequilin. Tablets for oral administration
are available in 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg, and 1.25 mg strengths of
conjugated estrogens.
Premarin 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg, and 1.25 mg tablets also contain the following inactive ingredients: calcium phosphate tribasic, hydroxypropyl cellulose, microcrystalline cellulose, powdered cellulose, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, sucrose, and titanium dioxide.
- 0.3 mg tablets also contain: D&C Yellow No. 10 and FD&C Blue
No. 2.
- 0.45 mg tablets also contain: FD&C Blue No. 2.
- 0.625 mg tablets also contain: FD&C Blue No. 2 and FD&C Red No.
40.
- 0.9 mg tablets also contain: D&C Red No. 30 and D&C Red No. 7.
- 1.25 mg tablets also contain: black iron oxide, D&C Yellow No. 10
and FD&C Yellow No. 6.
Premarin tablets comply with USP Dissolution Test criteria as outlined below:
Premarin 1.25 mg tablets                                                   USP
Dissolution Test 4
Premarin 0.3 mg, 0.45 mg and 0.625 mg tablets             USP
Dissolution Test 5
Premarin 0.9 mg tablets                                                     USP
Dissolution Test 6
Last reviewed on RxList: 3/28/2008




Premarin Drug Description
Premarin®
(conjugated estrogens) Tablets, USP

WARNINGS
ENDOMETRIAL CANCER
Adequate diagnostic measures, including endometrial sampling when indicated,
should be undertaken to rule out malignancy in all cases of undiagnosed persistent
or recurring abnormal vaginal bleeding. (See WARNINGS,
Malignant neoplasms, Endometrial cancer.)
CARDIOVASCULAR AND OTHER RISKS
Estrogens with or without progestins should not be used for the prevention
of cardiovascular disease or dementia. (See Clinical
Studies and WARNINGS, Cardiovascular
disorders and Dementia.)
The estrogen alone substudy of the Women's Health Initiative (WHI) reported
increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal
women (50 to 79 years of age) during 6.8 years and 7.1 years, respectively,
of treatment with daily oral conjugated estrogens (CE 0.625 mg), relative
to placebo. (See Clinical Studies and
WARNINGS, Cardiovascular disorders.)
The estrogen plus progestin substudy of WHI reported increased risks of myocardial
infarction, stroke, invasive breast cancer, pulmonary emboli, and DVT in postmenopausal
women (50 to 79 years of age) during 5.6 years of treatment with daily CE
0.625 mg combined with medroxyprogesterone acetate (MPA 2.5 mg), relative
to placebo. (See Clinical Studies and
WARNINGS, Cardiovascular disorders and
Malignant neoplasms, Breast cancer.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported
an increased risk of developing probable dementia in postmenopausal women
65 years of age or older during 5.2 years of treatment with daily CE 0.625
mg alone and during 4 years of treatment with daily CE 0.625 mg combined with
MPA 2.5 mg, relative to placebo. It is unknown whether this finding applies
to younger postmenopausal women. (See Clinical
Studies and WARNINGS, Dementia and
PRECAUTIONS, Geriatric Use.)
In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and MPA and other combinations and dosage forms of estrogens and progestins. Because of these risks, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

DRUG DESCRIPTION



What are the possible side effects of conjugated estrogens (Cenestin, Enjuvia, Premarin)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop taking this medication and call your doctor at once if you have any of these serious side effects:

chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, general ill feeling;
sudden numbness or weakness, especially on one side of the body;
sudden...
Read All Potential Side Effects for Premarin »




Premarin® (conjugated estrogens tablets, USP) for oral administration contains
a mixture of conjugated estrogens obtained exclusively from natural sources,
occurring as the sodium salts of water-soluble estrogen sulfates blended to
represent the average composition of material derived from pregnant mares' urine.
It is a mixture of sodium estrone sulfate and sodium equilin sulfate. It contains
as concomitant components, as sodium sulfate conjugates, 17α-dihydroequilin,
17α- estradiol, and 17β-dihydroequilin. Tablets for oral administration
are available in 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg, and 1.25 mg strengths of
conjugated estrogens.
Premarin 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg, and 1.25 mg tablets also contain the following inactive ingredients: calcium phosphate tribasic, hydroxypropyl cellulose, microcrystalline cellulose, powdered cellulose, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, sucrose, and titanium dioxide.
- 0.3 mg tablets also contain: D&C Yellow No. 10 and FD&C Blue
No. 2.
- 0.45 mg tablets also contain: FD&C Blue No. 2.
- 0.625 mg tablets also contain: FD&C Blue No. 2 and FD&C Red No.
40.
- 0.9 mg tablets also contain: D&C Red No. 30 and D&C Red No. 7.
- 1.25 mg tablets also contain: black iron oxide, D&C Yellow No. 10
and FD&C Yellow No. 6.
Premarin tablets comply with USP Dissolution Test criteria as outlined below:
Premarin 1.25 mg tablets                                                   USP
Dissolution Test 4
Premarin 0.3 mg, 0.45 mg and 0.625 mg tablets             USP
Dissolution Test 5
Premarin 0.9 mg tablets                                                     USP
Dissolution Test 6
Last reviewed on RxList: 3/28/2008




Premarin Drug Description
Premarin®
(conjugated estrogens) Tablets, USP

WARNINGS
ENDOMETRIAL CANCER
Adequate diagnostic measures, including endometrial sampling when indicated,
should be undertaken to rule out malignancy in all cases of undiagnosed persistent
or recurring abnormal vaginal bleeding. (See WARNINGS,
Malignant neoplasms, Endometrial cancer.)
CARDIOVASCULAR AND OTHER RISKS
Estrogens with or without progestins should not be used for the prevention
of cardiovascular disease or dementia. (See Clinical
Studies and WARNINGS, Cardiovascular
disorders and Dementia.)
The estrogen alone substudy of the Women's Health Initiative (WHI) reported
increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal
women (50 to 79 years of age) during 6.8 years and 7.1 years, respectively,
of treatment with daily oral conjugated estrogens (CE 0.625 mg), relative
to placebo. (See Clinical Studies and
WARNINGS, Cardiovascular disorders.)
The estrogen plus progestin substudy of WHI reported increased risks of myocardial
infarction, stroke, invasive breast cancer, pulmonary emboli, and DVT in postmenopausal
women (50 to 79 years of age) during 5.6 years of treatment with daily CE
0.625 mg combined with medroxyprogesterone acetate (MPA 2.5 mg), relative
to placebo. (See Clinical Studies and
WARNINGS, Cardiovascular disorders and
Malignant neoplasms, Breast cancer.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported
an increased risk of developing probable dementia in postmenopausal women
65 years of age or older during 5.2 years of treatment with daily CE 0.625
mg alone and during 4 years of treatment with daily CE 0.625 mg combined with
MPA 2.5 mg, relative to placebo. It is unknown whether this finding applies
to younger postmenopausal women. (See Clinical
Studies and WARNINGS, Dementia and
PRECAUTIONS, Geriatric Use.)
In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and MPA and other combinations and dosage forms of estrogens and progestins. Because of these risks, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

DRUG DESCRIPTION



What are the possible side effects of conjugated estrogens (Cenestin, Enjuvia, Premarin)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop taking this medication and call your doctor at once if you have any of these serious side effects:

chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, general ill feeling;
sudden numbness or weakness, especially on one side of the body;
sudden...
Read All Potential Side Effects for Premarin »




Premarin® (conjugated estrogens tablets, USP) for oral administration contains
a mixture of conjugated estrogens obtained exclusively from natural sources,
occurring as the sodium salts of water-soluble estrogen sulfates blended to
represent the average composition of material derived from pregnant mares' urine.
It is a mixture of sodium estrone sulfate and sodium equilin sulfate. It contains
as concomitant components, as sodium sulfate conjugates, 17α-dihydroequilin,
17α- estradiol, and 17β-dihydroequilin. Tablets for oral administration
are available in 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg, and 1.25 mg strengths of
conjugated estrogens.
Premarin 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg, and 1.25 mg tablets also contain the following inactive ingredients: calcium phosphate tribasic, hydroxypropyl cellulose, microcrystalline cellulose, powdered cellulose, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, sucrose, and titanium dioxide.
- 0.3 mg tablets also contain: D&C Yellow No. 10 and FD&C Blue
No. 2.
- 0.45 mg tablets also contain: FD&C Blue No. 2.
- 0.625 mg tablets also contain: FD&C Blue No. 2 and FD&C Red No.
40.
- 0.9 mg tablets also contain: D&C Red No. 30 and D&C Red No. 7.
- 1.25 mg tablets also contain: black iron oxide, D&C Yellow No. 10
and FD&C Yellow No. 6.
Premarin tablets comply with USP Dissolution Test criteria as outlined below:
Premarin 1.25 mg tablets                                                   USP
Dissolution Test 4
Premarin 0.3 mg, 0.45 mg and 0.625 mg tablets             USP
Dissolution Test 5
Premarin 0.9 mg tablets                                                     USP
Dissolution Test 6
Last reviewed on RxList: 3/28/2008





Other reviews about Conjugated Estrogens on wordpress

Premarin
  by mp3musiclisten
Buy Premarin Drug Name. Premarin (Conjugated equine estrogens) Drug Uses. Conjugated estrogens are used for treating the symptoms of menopause including hot flashes, vaginal dryness, and vaginal atrophy. They also are used […]


Premarin® (conjugated estrogens) Tablets, USP
  by kanlayanee
[caption id="" align="alignnone" width="288" caption="PREMARIN 0.3 MG TABLET"][/caption] Adult Min/Max Dose: 0.3mg/30.0mg Common Dosages by Indication: Atrophic Vaginitis associated with Menopause take 1 tablet (0.3 mg) po once daily take 1 tablet (0.3 […]


PREMPRO™,PREMPHASE® (conjugated estrogens/medroxyprogesterone acetate) Tablets
  by kanlayanee
[caption id="" align="alignnone" width="251" caption="Brand names Premphase®, Prempro®"][/caption] USES: This medication is used to reduce menopause symptoms. It helps reduce episodes of flushing and sweating of the upper body and […]


More Good News for Women: Synthetic, Prescription HRT Shrinks the Brain
  by insightanalytical
~~By InsightAnalytical-GRL Here's some cheery news to end the week with.  The story will only be available until April 12, 2009 for some reason; I guess this is going […]


Post Menopausal Hormone Therapy
  by joelnathanmd
Osteopenia or osteoporosis, atrophic vaginits, weight gain and loss of libido are all signs of decreased hormone production in the menopausal female. Re-evaluation of the World Health Initiative […]


Estrogen part 3.
  by joelnathanmd
It is important to note that an increased risk of blood clots was found in the WHI study released in 2002. Both bioidentical as well as conjugated equine […]


Pfizer to Withdraw Fablyn NDAs
  by Vivian
Written by JANE ALLIN Research Analyst [caption id="attachment_4961" align="alignleft" width="250" caption="For every 150 women who stop taking Premarin, one mare is spared from the “pee line” and seven or eight […]


Pfizer to Withdraw Fablyn NDAs
  by Vivian
Written by JANE ALLIN Research Analyst | Int'l Fund for Horses [caption id="attachment_4961" align="alignleft" width="250" caption="For every 150 women who stop taking Premarin, one mare is spared from the “pee […]


The Rise and Fall of the PMU Industry
  by Vivian
Written by JANE ALLIN Research Analyst | Int'l Fund for Horses Page 1 [caption id="attachment_10505" align="alignleft" width="203" caption="Pharmaceutical giant Pfizer acquired major drug manufacturer, Wyeth, for 68 billion dollars. Missing from […]


Premarin® - A Timeline
  by Vivian
Menopause – The “Disease” Page 1 1686: Fourteen “witches” are executed at Salem – thirteen of them are menopausal women. 1821: A French physician named de Gardanne coins the term […]



Other reviews about Conjugated Estrogens on web:

Explains the medication estrogens conjugated (Premarin), a drug used for treating the symptoms of menopause including hot flashes, vaginal dryness, and vaginal atrophy. estrogens conjugated (Premarin) - drug class, medical uses ...


Learn about the prescription medication Premarin (Conjugated Estrogens), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Premarin (Conjugated Estrogens) Drug Information: Uses, Side ...


Premarin is the commercial name for compound drug consisting primarily of conjugated estrogens. Isolated from mare's urine (PRE gnant MAR es' ur IN e), it is manufactured by Wyeth ... Premarin - Wikipedia, the free encyclopedia


Physician reviewed conjugated estrogens (oral) patient information - includes conjugated estrogens description, dosage and directions. conjugated estrogens (oral) medical facts from Drugs.com


Conjugated Estrogens Brand names: Cenestin™Cenestin®Enjuvia™Premarin® Chemical formula: Drug Forms: Synthetic Conjugated Estrogens Conjugated Estrogens: Information from Answers.com


All about Conjugated Estrogens. View complete and up to date Conjugated Estrogens information - part of the Drugs.com trusted medication database. Conjugated Estrogens Facts and Comparisons at Drugs.com


Find patient medical information for Conjugated Estrogens Oral on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings. Conjugated Estrogens Oral : Uses, Side Effects, Interactions ...


Conjugated estrogens is a blend of estrogens that is found in several medicines for menopause treatment. This eMedTV page offers an overview of these estrogens, including ... Conjugated Estrogens


Resource URI: http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00286 Conjugated Estrogens | D2R Server publishing the DrugBank Database ...


What is Conjugated Estrogens? Estrogen is a female sex hormone produced by the ovaries. Estrogen is necessary for many processes in the body. Conjugated estrogens are a mixture of ... Conjugated Estrogens - Drugs & Treatments - Revolution Health





Featured Reviews

Reviews BenzaClin

BenzaClin Drug Description BenzaClin® Topical Gel (clindamycin - benzoyl peroxide) Gel Topical Gel: clindamycin (1%) as clindamycin phosphate, benzoyl peroxide (5%) For Dermatological Use Only - Not for Ophthalmic Use *Reconstitute...
Read More  |  Review This
Reviews Pneumovax

Pneumovax Drug Description PNEUMOVAX® 23 (pneumococcal) Vaccine Polyvalent DRUG DESCRIPTION What are the possible side effects of pneumococcal polysaccharide vaccine (Pneumovax 23, Pnu-Imune 23)? Getting pneumococcal disease...
Read More  |  Review This
Reviews Boniva

Boniva Drug Description BONIVA® (ibandronate sodium) Tablets DRUG DESCRIPTION What are the possible side effects of ibandronate (Boniva)? Get emergency medical help if you have any of these signs of an allergic reaction: hives;...
Read More  |  Review This
Reviews Acetylcysteine Solution

Acetylcysteine Solution Drug Description ACETYLCYSTEINE SOLUTION, USP DRUG DESCRIPTION Acetylcysteine is the nonproprietary name for the N-acetyl derivative of the naturally occurring amino acid, L-cysteine. Chemically, it is N-acetyl-L-cysteine. The...
Read More  |  Review This
Reviews Flunisolide Nasal Spray .025%

Flunisolide Nasal Solution Drug Description Flunisolide Nasal Solution USP, 0.025% (Nasal Spray) (29 mcg flunisolide per spray) For Intranasal Use Only DRUG DESCRIPTION Flunisolide, the active component of flunisolide nasal solution,...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....